Moderna Inc. mentioned on Thursday that it’s growing a single-dose vaccine that mixes a booster dose in opposition to COVID-19 and a booster dose in opposition to influenza.
“Our primary precedence as an organization at the moment is to carry to market an annual respiratory booster vaccine, which we plan to all the time customise and improve,” CEO Stéphane Bancel mentioned throughout Moderna’s R&D day.
The corporate offered an replace on the continued mid-stage trial of its licensed COVID-19 vaccine in youngsters six months to beneath 12 years of age.
Learn extra:
Novavax begins preliminary trials of mixed influenza and COVID-19 vaccines
Moderna’s vaccine, which acquired emergency approval for individuals 18 years of age and older in america in December, is at present beneath FDA evaluate to be used in adolescents.
As a part of a youngsters’s trial, the corporate mentioned it can take a look at 50 micrograms of its vaccine in a research group of 4,000 youngsters ages 6 to beneath 12.
Moderna says dose choice research for various age teams, resembling these aged two to beneath six and people six months to beneath two, are nonetheless ongoing.
Pfizer Inc’s rival vaccine. and German associate BioNTech have been licensed for ages 12 to fifteen earlier this yr.
Novavax Inc. mentioned Wednesday that it has begun an early-stage research to check its mixed flu and COVID-19 vaccines.
(Reporting by Manojna Maddipatla in Bengaluru; Modifying by Vinay Dwivedi and Shinjini Ganguli)
View hyperlinks »
